For the last 80 years, softgel technology has brought poorly water soluble and/or permeable BCS II & IV compounds to market by improving their bioavailability. Gelatin has predominantly been the ingredient of choice for the softgel shell material for lipid base formulation. The significant interest in semisolid systems for the potential of extended release profiles has prompted researchers to develop alternative encapsulating systems.
Orally dissolving tablets (ODT) are designed to dissolve rapidly on contact with saliva, therefore eliminating the need to chew the tablet, swallow the intact tablet, or take the tablet with liquids. View the webinar to get an overview of Zydis ODT technology. The webinar also presents the highlights of Zydis Ultra that can provide a better solution in terms of improved taste masking, functional coating, and a wide range of applications.
ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis, and treatment of allergies. By partnering with Catalent, ALK-Abelló was able to realize the first patient-friendly allergen immunotherapy and deliver on their promise of improving the quality of life for allergy patients.
With the Better Treatments by Design process, Catalent aims to achieve optimal outcomes for innovators, prescribers, and patients. By applying advanced dose design principles early we can help you achieve optimal absorption profiles as well as improve patient adherence and compliance, leading to greater payer acceptance, more scripts, and potentially better patient outcomes.